HER2 status in primary stage T1 urothelial cell carcinoma of the urinary bladder

References

• Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118–45.
   PubMed Web of Science ®Google Scholar
• Moelans CB, van Diest PJ, Milne AN, Offerhaus GJ. Her-2/neu testing and therapy in gastroesophageal adenocarcinoma. Pathol Res Int 2011;2011:674182.
   Google Scholar
• Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol 2011;18:53–9.
   PubMed Web of Science ®Google Scholar
• Urruticoechea A, Alemany R, Balart J, Villanueva A, Vinals F, Capella G. Recent advances in cancer therapy: an overview. Curr Pharm Des 2010;16:3–10.
   PubMed Web of Science ®Google Scholar
• Herr HW, Donat SM, Dalbagni G. Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? J Urol 2007;177:75–9; discussion 9.
   PubMed Web of Science ®Google Scholar
• Andius P, Holmang S. Bacillus Calmette-Guerin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression. BJU Int 2004;93:980–4.
   PubMed Web of Science ®Google Scholar
• Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 2003;169:96–100; discussion.
   PubMed Web of Science ®Google Scholar
• Ely S. Personalized medicine: individualized care of cancer patients. Transl Res 2009;154:303–8.
   PubMed Web of Science ®Google Scholar
• Sobin LH, Fleming ID. TNM classification of malignant tumors. 5th ed. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997;80:1803–4.
   PubMed Web of Science ®Google Scholar
• Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998;22:1435–48.
   PubMed Web of Science ®Google Scholar
• Reuter VE, Epstein JI, Amin MB, Mostofi FK. The “WHO/ISUP consensus classification of urothelial (transitional cell) neoplasms”: continued discussion. Hum Pathol 1999;30:879–80.
   PubMed Web of Science ®Google Scholar
• Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000;163:73–8.
   PubMed Web of Science ®Google Scholar
• Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, Matos T, Cordon-Cardo C. Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol 2010;28:401–8.
   PubMed Web of Science ®Google Scholar
• Lindgren D, Frigyesi A, Gudjonsson S, Sjodahl G, Hallden C, Chebil G, Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 2010;70:3463–72.
   PubMed Web of Science ®Google Scholar
• Laé M, Couturier J, Oudard S, Radvanyi F, Beuzeboc P, Vieillefond A. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol 2010;21:815–9.
   PubMed Web of Science ®Google Scholar
• Caner V, Turk NS, Duzcan F, Tufan NL, Kelten EC, Zencir S, No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas. Pathol Oncol Res 2008;14:261–6.
   PubMed Web of Science ®Google Scholar
• Simonetti S, Russo R, Ciancia G, Altieri V, De Rosa G, Insabato L. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and FISH analysis of c-erbB-2 gene and chromosome 17. Int J Surg Pathol 2009;17:198–205.
   PubMed Web of Science ®Google Scholar
• Gandour-Edwards R, Lara PN Jr, Folkins AK, LaSalle JM, Beckett L, Li Y, Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 2002;95:1009–15.
   PubMed Web of Science ®Google Scholar
• Munzone E, Nole F, Goldhirsch A, Botteri E, Esposito A, Zorzino L, Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. Clin Breast Cancer 2010;10:392–7.
   PubMed Web of Science ®Google Scholar
• Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000;18:3651–64.
   PubMed Web of Science ®Google Scholar
• Ryden L, Haglund M, Bendahl PO, Hatschek T, Kolaric A, Kovacs A, Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast cancer: a national survey performed at pathology departments in Sweden. Acta Oncol 2009;48:860–6.
   PubMed Web of Science ®Google Scholar
• Brugmann A, Lelkaitis G, Nielsen S, Jensen KG, Jensen V. Testing HER2 in breast cancer: a comparative study on BRISH, FISH, and IHC. Appl Immunohistochem Mol Morphol 2011;19:203–11.
   PubMedGoogle Scholar
• Marin AP, Arranz EE, Sanchez AR, Aunon PZ, Baron MG. Role of anti-Her-2 therapy in bladder carcinoma. J Cancer Res Clin Oncol 2010;136:1915–20.
   PubMed Web of Science ®Google Scholar